Abstract
Laminin-332 and α6β4 integrin is major hemidesmosome components in the skin. As many studies have shown that laminin-332 and α6β4 integrin play important roles in tumor progression via activation of phosphatidylinositol-3 kinase signaling, understanding of the molecular mechanisms of them could lead to a new drug for cancer therapy.
Keywords: Laminin-332, α6β4 integrin, basement membrane, extracellular matrix, tumor, cell migration, cell adhesion, ErbB2
Mini-Reviews in Medicinal Chemistry
Title: Roles of Laminin-332 and α6β4 Integrin in Tumor Progression
Volume: 9 Issue: 11
Author(s): Y. Kariya, Y Kariya and J. Gu
Affiliation:
Keywords: Laminin-332, α6β4 integrin, basement membrane, extracellular matrix, tumor, cell migration, cell adhesion, ErbB2
Abstract: Laminin-332 and α6β4 integrin is major hemidesmosome components in the skin. As many studies have shown that laminin-332 and α6β4 integrin play important roles in tumor progression via activation of phosphatidylinositol-3 kinase signaling, understanding of the molecular mechanisms of them could lead to a new drug for cancer therapy.
Export Options
About this article
Cite this article as:
Kariya Y., Y Kariya and Gu J., Roles of Laminin-332 and α6β4 Integrin in Tumor Progression, Mini-Reviews in Medicinal Chemistry 2009; 9 (11) . https://dx.doi.org/10.2174/138955709789878114
DOI https://dx.doi.org/10.2174/138955709789878114 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Particle-based Vaccines for HIV-1 Infection
Current Drug Targets - Infectious Disorders Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Emerging Immunotargets in Bladder Cancer
Current Drug Targets Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors
Current Genomics Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Management of Vulvar Cancer
Reviews on Recent Clinical Trials Decreasing the Metastatic Potential in Cancers - Targeting the Heparan Sulfate Proteoglycans
Current Drug Targets Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Effects of Highly Active Antiretroviral Therapy on HIV-1-Associated Oral Complications
Current HIV Research Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment
Current Drug Metabolism Thrombospondin and Apoptosis: Molecular Mechanisms and Use for Design of Complementation Treatments
Current Drug Targets Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Optimizing Target Selection and Development Strategy in Cancer Treatment; The Next Wave
Current Medicinal Chemistry - Anti-Cancer Agents